<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar major depression in adults: Choosing treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar major depression in adults: Choosing treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar major depression in adults: Choosing treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard C Shelton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William V Bobo, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H23270348"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is marked by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and nearly always includes episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Observational studies consistently show that depressive episodes predominate the clinical course of bipolar disorder [<a href="#rid2">2,3</a>]. Compared with manic and hypomanic episodes, bipolar depressive episodes and residual bipolar depressive symptoms account for a greater proportion of long-term morbidity, impaired functioning, and risk of suicide [<a href="#rid4">4,5</a>].</p><p>As a result, improved treatment of bipolar major depression is a patient priority. An internet based survey from 11 countries, which asked patients with bipolar disorder (n = 1300) which aspects of care they would most like to see improved, better treatment of depression was endorsed by the largest number (&gt;40 percent) [<a href="#rid6">6</a>]. The second and third leading aspects of care that patients would most like to see improved were avoiding weight gain and preventing relapse of depressive episodes.</p><p>This topic reviews choosing treatment for adults with bipolar major depression. Other topics discuss the general principles of treating bipolar major depression in adults, the efficacy and adverse effects of antidepressants and second-generation antipsychotics for bipolar major depression in adults, investigational and nonstandard approaches to treating bipolar major depression in adults, choosing pharmacotherapy for adults with acute mania and hypomania, choosing maintenance treatment for adults, and choosing pharmacotherapy for pediatric and geriatric bipolar major depression.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115481.html" rel="external">"Bipolar major depression in adults: Investigational and nonstandard approaches to treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p></p><p class="headingAnchor" id="H181811569"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H709534888"><span class="h2">Bipolar disorder</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by periods of pathologic mood elevation (mania or hypomania) [<a href="#rid1">1</a>]. Patients with bipolar I disorder experience manic episodes  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and nearly always experience both hypomanic episodes  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and major depressive episodes  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>). Bipolar II disorder is characterized by at least one episode of hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and one or more major depressive episodes. In addition, psychotic features such as delusions and hallucinations frequently accompany bipolar depressive episodes, particularly in patients with bipolar I disorder [<a href="#rid7">7</a>].</p><p>Additional information about the clinical features and diagnosis of bipolar disorder, including bipolar major depression, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis"</a>.)</p><p class="headingAnchor" id="H4055331476"><span class="h2">Antimanic drug</span><span class="headingEndMark"> — </span>We use the term antimanic drug to refer to medications that can reduce acute symptoms of mania/hypomania, without causing a switch to the opposite polarity. Examples include <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, antiepileptics such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and second-generation antipsychotics such as <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>.</p><p>By contrast, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> does not reduce acute symptoms of mania/hypomania and is thus not an antimanic drug per se. However, lamotrigine can prevent episodes of mania. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lamotrigine'</a>.)</p><p class="headingAnchor" id="H23270426"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The general principles and issues that are involved in treating bipolar major depression in adults include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial assessment</p><p class="bulletIndent1"><span class="glyph">●</span>Goals</p><p class="bulletIndent1"><span class="glyph">●</span>Setting</p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of an adequate drug trial</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring</p><p class="bulletIndent1"><span class="glyph">●</span>Adjunctive psychotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidity</p><p></p><p>These general principles are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p class="headingAnchor" id="H3116229391"><span class="h2">Pharmacotherapy plus psychotherapy</span><span class="headingEndMark"> — </span>Although the cornerstone of treatment for acute bipolar major depression is pharmacotherapy, we frequently prescribe adjunctive psychotherapy to improve outcomes [<a href="#rid8">8</a>]. At minimum, all patients should be educated about their illness to improve acceptance of the diagnosis and need for treatment, optimize adherence to treatment, and facilitate recognition and responses to early warning signs of relapse [<a href="#rid9">9</a>]. Psychoeducation also includes information about self-management, such as creating structure and adopting daily routines, being physically active, monitoring symptoms, and avoiding potentially mood destabilizing activities such as alcohol misuse and use of cannabis and other drugs.</p><p>Evidence-based, adjunctive psychotherapies for managing acute bipolar major depression include cognitive-behavioral therapy, interpersonal and social rhythm therapy, group psychoeducation, and family-focused therapy. (See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment", section on 'Adjunctive psychotherapy'</a>.)</p><p class="headingAnchor" id="H23270433"><span class="h1">BIPOLAR I MAJOR DEPRESSION, NO ANTIMANIC DRUG THERAPY</span><span class="headingEndMark"> — </span>This section describes acute treatment of patients who present with bipolar I major depression in the absence of antimanic drug therapy. (See <a class="local">'Antimanic drug'</a> above.)</p><p class="headingAnchor" id="H2681143167"><span class="h2">Choosing pharmacotherapy</span><span class="headingEndMark"> — </span>We suggest that acute treatment of bipolar I major depression in patients who are currently not treated with an antimanic drug (see <a class="local">'Antimanic drug'</a> above) proceed according to the sequence described in the subsections below. Patients start with first-line medications and depending upon symptom improvement and tolerability, either continue the treatment regimen or progress to the next step [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>First-line medications – Monotherapy with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second-line medications – If <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy and <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> monotherapy are each ineffective or intolerable, next step treatment options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> (divalproex) monotherapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third-line medications – If second-line medication regimens are not effective or tolerable, next step treatment options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monotherapy with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monotherapy with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other antimanic drug combinations (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> plus an antidepressant such as a selective-serotonin reuptake inhibitor (SSRI; eg, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>) or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with a second generation antipsychotic (usually <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>) plus an antidepressant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment-refractory patients – Electroconvulsive therapy (ECT)</p><p></p><p>ECT frequently provides a rapid clinical response and may thus be indicated as initial treatment in urgent clinical situations that are life-threatening, such as persistent suicidal behavior or gross impairment of functioning (eg, dehydration and malnutrition secondary to refusal of liquids and food) [<a href="#rid9">9-11</a>]. In addition, ECT is reasonable as next step treatment for patients with bipolar major depression who are severely ill (eg, persistent suicidal ideation with a plan) and do not respond to or tolerate multiple (eg three to five) medication trials.</p><p>The specific treatment choice depends upon prior treatment history, treatment side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 7</a>), comorbid illnesses, patient preferences, and cost. As an example, clinicians often avoid <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> in patients who are overweight and avoid <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> in patients sensitive to dyspepsia.</p><p>The duration of an adequate trial for a particular medication regimen is discussed separately. (See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment", section on 'Duration of an adequate drug trial'</a>.)</p><p class="headingAnchor" id="H23270378"><span class="h3">First-line medications</span><span class="headingEndMark"> — </span>For patients with acute bipolar I major depression who are not taking an antimanic drug, we suggest either <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> as initial pharmacotherapy [<a href="#rid9">9,12</a>]. We generally start with quetiapine because it has been more widely studied than lurasidone in acutely depressed patients. In addition, using quetiapine to treat bipolar I major depression is advantageous in that the drug has demonstrated efficacy for maintenance treatment. However, no published head-to-head trials have compared quetiapine with lurasidone, and it is reasonable to start with lurasidone first. Multiple practice guidelines recommend treating bipolar depression with quetiapine or lurasidone, either as initial treatment or next step treatment [<a href="#rid10">10,11,13-17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quetiapine</strong> – <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a> is typically administered at bedtime because it frequently causes sedation. The drug is generally started at a dose of 50 mg at bedtime and titrated up by increments of 50 to 100 mg/day over one week to a target dose of 300 mg/day [<a href="#rid18">18-21</a>]. There is no compelling evidence supporting a target dose less than 300 mg/day [<a href="#rid22">22</a>]. Patients who are sensitive to adverse effects may start with 25 mg at bedtime, and increase the dose more slowly. The efficacy of immediate- and extended-release quetiapine for acute bipolar major depression is comparable [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Randomized trials indicate that doses of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> 600 mg/day are no more effective than 300 mg/day [<a href="#rid24">24</a>]. Nevertheless, in our clinical experience, larger doses (eg, 800 mg/day) may be required for patients with an incomplete response at lower doses. In patients who have difficulty tolerating a relatively large single dose, the drug can be administered twice daily, with most of the drug given at night (eg, 100 mg in the morning and 500 mg at bedtime).</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> for acute bipolar I or II major depression is well established, based upon multiple meta-analyses of randomized trials. The efficacy and adverse effects of quetiapine in acute treatment are discussed separately, as are the maintenance treatment efficacy data. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Quetiapine'</a> and  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Quetiapine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lurasidone</strong> – <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">Lurasidone</a> is started at 20 mg once daily in the evening and is taken with a meal (eg, &gt;350 calories) or 30 minutes thereafter to ensure adequate bioavailability and to limit gastrointestinal side effects [<a href="#rid25">25,26</a>]. The dose can be increased every two to seven days by increments of 20 mg per day to optimize effectiveness and tolerability. The target dose range is 20 to 120 mg per day. Side effects that may limit dose increases include headache, nausea, and akathisia. One potential advantage of lurasidone is that it typically does not cause weight gain and adverse metabolic effects, including elevation of blood glucose [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">The efficacy and adverse effects of <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> in patients in acute bipolar I major depression are discussed separately. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Lurasidone'</a>.)</p><p></p><p>For patients with bipolar I major depression who do not respond to treatment with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> is started and titrated up. Response is defined as substantial improvement in the number, intensity, and frequency of symptoms and is often operationalized in studies as reduction of baseline symptoms ≥50 percent. The failed medication is generally tapered by the same amount for each dose decrease. As an example, quetiapine 300 mg/day is decreased by 50 mg per day, every one to three days. In the same manner, patients who start with lurasidone and do not respond are switched to quetiapine.</p><p>In addition, ECT frequently provides a rapid clinical response and may thus be indicated as first-line treatment in certain urgent clinical situations that are life-threatening or characterized by gross impairment of functioning. (See <a class="local">'Treatment-refractory patients'</a> below.)</p><p class="headingAnchor" id="H23270384"><span class="h3">Second-line medications</span><span class="headingEndMark"> — </span>Patients with bipolar I major depression may not respond to or tolerate initial treatment with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy and <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> monotherapy. For these patients, we suggest <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> (divalproex) monotherapy, combination therapy with quetiapine or lurasidone plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or valproate, and combination therapy with lithium plus valproate or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>. [<a href="#rid9">9,12</a>]. Using these drugs for bipolar major depression is consistent with multiple treatment guidelines [<a href="#rid10">10,11,13-17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olanzapine</strong><strong> plus </strong><strong>fluoxetine</strong> – The efficacy of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> is well established, based upon randomized trials that compared the combination with active treatments (eg, olanzapine monotherapy and <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> monotherapy), as well as placebo. As an example, a network (multiple treatment) meta-analysis of 29 randomized trials evaluated the efficacy of 13 medication regimens in patients who were treated for 4 to 16 weeks (n &gt;8000) [<a href="#rid28">28</a>]. The analysis ranked the efficacy of medications by using results from direct comparisons between the drugs, as well as indirectly comparing drugs through their relative effect with a common comparator (typically placebo). The most efficacious drug regimen among those studied was olanzapine plus fluoxetine.</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> is reserved for treatment-resistant patients because of problematic weight gain and metabolic disorders. In addition, the adverse effects of olanzapine often preclude using the drug as a maintenance treatment, and we recommend that antidepressants be avoided as maintenance treatments in bipolar disorder. The efficacy and adverse effects of the drug combination for acute bipolar major depression are described elsewhere, as are the efficacy and adverse effects of olanzapine monotherapy for maintenance treatment. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Acute treatment'</a> and  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Olanzapine'</a>.)</p><p></p><p class="bulletIndent1">Clinicians can prescribe <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> as two separate pills or a as a single pill. Individual pills are generally recommended because of cost and flexibility in dosing each medication. If each drug is prescribed as a separate pill, the starting dose of olanzapine is typically 5 mg once daily at bedtime [<a href="#rid29">29,30</a>]. The dose can then be titrated up by increments of 5 mg/day every one to seven days, depending upon efficacy and tolerability; the maximum dose is to 15 mg/day. For patients sensitive to adverse effects, the dose can be started at 2.5 mg/day, titrated up to 5 mg/day within one to seven days, and further titrated by 2.5 or 5 mg/day every one to seven days. Concurrent with administration of olanzapine, fluoxetine is usually started at 20 mg/day at bedtime. The dose can then be titrated up by increments of 10 or 20 mg/day every one to seven days, depending upon efficacy and tolerability; the maximum dose is to 50 mg/day.</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> is prescribed as a single pill (<a class="drug drug_general" data-topicid="10088" href="/d/drug information/10088.html" rel="external">olanzapine-fluoxetine</a> combination), the starting dose is 6 and 25 mg/day [<a href="#rid29">29</a>]. The dose can then be titrated up to 6 and 50 mg/day after one to seven days, depending upon efficacy and tolerability; subsequently, the dose can be increased to 12 and 50 mg/day.</p><p></p><p class="bulletIndent1">If a patient treated with <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> switches to mania or hypomania, clinicians should immediately discontinue the fluoxetine [<a href="#rid31">31</a>]. Abruptly stopping the drug should not cause discontinuation symptoms because the half-life of fluoxetine is long. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults", section on 'SSRIs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong><strong> (divalproex)</strong> – Using <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> monotherapy to treat acute bipolar I major depression is advantageous in that the drug has demonstrated efficacy for maintenance treatment. However, the drug is often avoided in women of childbearing age due to concerns about teratogenicity [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Valproate'</a> and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Valproate'</a>.)</p><p></p><p class="bulletIndent1">For patients with bipolar disorder, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> is usually started at a dose of 250 mg two or three times per day. The dose is increased by 250 mg to 500 mg every one to three days as tolerated to reach a therapeutic serum level, which generally occurs with 1500 mg to 2500 mg per day [<a href="#rid32">32-35</a>]. Valproate is usually administered twice daily (although a once-a-day formulation is available in the United States).</p><p></p><p class="bulletIndent1">We suggest drawing <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> serum levels three to five days after each dose increase and prescribing the drug to achieve a target serum level between 50 and 125 mcg/mL [<a href="#rid32">32,34,35</a>]. Levels should be drawn 12 hours after the last dose and generally collected in the morning, before the first dose of the day. After target serum levels have been achieved, levels should be checked at 6- to 12-month intervals and are particularly useful in patients receiving medications that affect valproate concentrations and to confirm adherence. Some patients may not require regular valproate levels, and one review concluded that clinical observation of efficacy and toxicity can be used to guide some dose adjustments [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Common side effects of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> include weight gain, nausea, vomiting, hair loss, easy bruising, and tremor  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a>); divalproex is a formulation of valproate that can minimize gastrointestinal distress. In addition, valproate is rarely associated with hepatic failure and thrombocytopenia  (<a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 6</a>); liver function tests and platelets should thus be monitored at 6- to 12-month intervals in all patients taking the drug [<a href="#rid37">37-39</a>]. (The US Food and Drug Administration [FDA] recommends checking liver function tests prior to initiating treatment and at frequent intervals thereafter, especially during the first six months.) Valproate rarely causes pancreatitis; symptoms of abdominal pain and vomiting should prompt an assessment that includes a serum amylase and lipase. In women of reproductive potential, valproate is associated with a higher risk of menstrual disturbances and polycystic ovary syndrome, compared with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1">Additional information about the pharmacology of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, its adverse effects, and available preparations are discussed separately, as well as problems using valproate in women of childbearing age. (See  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling"</a>.)</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> includes multiple meta-analyses of randomized trials [<a href="#rid28">28,42,43</a>]. As an example, a meta-analysis of four small trials, lasting six or eight weeks, compared valproate with placebo in 142 patients with bipolar I or II depression (total n = 142) [<a href="#rid44">44</a>]. Remission occurred in more patients who received valproate than placebo (relative risk 1.61, 95% CI 1.02-2.53; 41 versus 24 percent of patients). In addition, a pooled analysis found that discontinuation of treatment due to side effects was comparable for valproate and placebo (4 and 3 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><strong>quetiapine</strong><strong> or </strong><strong>lurasidone</strong><strong> plus </strong><strong>lithium</strong><strong> or </strong><strong>valproate</strong> – We reserve combination therapy for cases in which monotherapy with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> yields insufficient benefit. Monotherapy is associated with better adherence and fewer adverse effects than combination therapy. Although lurasidone plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> has been approved for acute bipolar I major depression, we nevertheless recommend combined lurasidone and mood stabilizer treatment as a second-line treatment option.</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><strong>lithium</strong><strong> plus </strong><strong>valproate</strong><strong> or </strong><strong>lamotrigine</strong> – The use of these medication regimens is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p>In addition, for patients with bipolar major depression who are severely ill (eg, persistent suicidal ideation with a plan) and have not responded to multiple (eg, three to five) pharmacotherapy trials, electroconvulsive therapy may be indicated. (See <a class="local">'Treatment-refractory patients'</a> below.)</p><p class="headingAnchor" id="H2097130101"><span class="h3">Third-line medications</span><span class="headingEndMark"> — </span>Patients with bipolar I major depression may not respond to or tolerate initial and next step treatments with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> (divalproex), combination therapy with quetiapine or lurasidone plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or valproate, and combination therapy with lithium plus valproate or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>. For these patients, we suggest monotherapy with lamotrigine or lithium [<a href="#rid9">9</a>]. However, for patients who were not previously treated with olanzapine plus fluoxetine during the current depressive episode (eg, patients with a prior history of poor response to adjunctive antidepressants), olanzapine monotherapy is a reasonable alternative. Other reasonable alternatives include monotherapy with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a>, and combination therapy with olanzapine plus lithium or valproate. In addition, it is reasonable to prescribe other antimanic drug combinations (eg, lithium plus carbamazepine), as well as combination therapy with lithium or valproate plus an antidepressant such as an SSRI (eg, fluoxetine) or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, and combination therapy with a second generation antipsychotic (usually quetiapine, lurasidone, or olanzapine) plus an antidepressant. The use of lamotrigine, lithium, olanzapine, carbamazepine, cariprazine, or combination pharmacotherapy is consistent with multiple treatment guidelines [<a href="#rid10">10,11,13-15,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong> – Using <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> monotherapy to treat acute bipolar I major depression is advantageous in that the drug is generally well tolerated and has demonstrated efficacy for maintenance treatment [<a href="#rid9">9,45</a>]. However, a disadvantage in using lamotrigine as an acute treatment is that its efficacy is modest and clinicians need to titrate the dose slowly to reduce the risk of life-threatening skin rashes.</p><p></p><p class="bulletIndent1">The starting dose of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is usually 25 mg once per day for two weeks, which is then increased to 25 mg twice per day for weeks 3 and 4 [<a href="#rid46">46,47</a>]. The dose is then titrated up, depending upon symptomatic improvement and tolerability, by 25 to 50 mg/day, one week at a time for each increase. The target dose ranges from 100 to 400 mg/day; in many studies, the target dose was 200 mg/day. An extended-release formulation is available for once a day dosing. The starting dose of lamotrigine must be lower and the dose-titration schedule more conservative for patients already taking <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> (which can interfere with the conjugation of lamotrigine and therefore increase the risk of severe rash).</p><p></p><p class="bulletIndent1">The slow titration of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> appears to reduce the risk of serious and life-threatening skin rash, defined as any rash associated with hospitalization, discontinuation of lamotrigine, or Stevens-Johnson syndrome (toxic epidermal necrolysis). In four acute and four maintenance randomized trials that slowly titrated the dose of lamotrigine in 827 patients with bipolar disorder, no cases of serious rash occurred; among the 685 patients who received placebo, there was one case of serious rash [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> can be efficacious for treating acute bipolar I or II major depression, but the clinical effect is generally modest, and the benefit appears to be greater in patients with more severe symptoms [<a href="#rid28">28</a>]. Evidence for the efficacy of lamotrigine includes a meta-analysis of patient level data from five randomized trials (n = 1072) that compared lamotrigine (100 to 400 mg per day) with placebo for 7 to 10 weeks [<a href="#rid46">46</a>]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received lamotrigine than placebo (44 versus 35 percent). In subgroup analyses, the benefit of lamotrigine was comparable for bipolar I and bipolar II major depression; however, lamotrigine was superior to placebo for severe depression at baseline but not for moderate depression. The modest benefit found in these randomized trials may be due in part to the six-week dose-titration schedule required to reach the target dose, in trials that generally lasted only eight weeks [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">The tolerability of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> in patients with bipolar disorder is generally good [<a href="#rid48">48</a>]. Pooled analyses from four acute and four maintenance randomized trials (total n = 1512 patients) found that discontinuation of treatment due to adverse events was comparable for lamotrigine and placebo (12 and 10 percent), and the incidence of any specific side effect that occurred was also comparable for the two groups [<a href="#rid47">47</a>]. The most common side effects of lamotrigine and placebo were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Headache – 25 and 21 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Nausea – 14 and 15 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Infection – 11 and 11 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Dizziness – 9 and 8 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Any rash – 9 and 8 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Somnolence – 9 and 6 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Pain – 9 and 7 percent</p><p></p><p class="bulletIndent1">In patients with pre-existing cardiac disease, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> may be associated with an increased risk of arrythmias. Following reports of abnormal electrocardiographic findings, chest pain, loss of consciousness, and cardiac arrest in patients treated with lamotrigine, the FDA conducted in vitro studies of the drug at therapeutically relevant serum concentrations [<a href="#rid49">49</a>]. The results prompted the agency to issue a warning that lamotrigine can slow ventricular conduction (widen QRS) and increase the risk of serious, potentially life-threatening arrythmias in patients with clinically important structural or functional cardiac disease (eg, heart failure, valvular heart disease, or conduction system disease), patients with multiple risk factors for coronary artery disease, or patients using other sodium channel blockers. Although the benefits of lamotrigine in patients with bipolar major depression and underlying heart disease may outweigh the risks, we suggest that clinicians attempt to avoid the drug in these patients.</p><p></p><p class="bulletIndent1">Additional information about the side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is discussed separately in the context of epilepsy. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'</a>.)</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> as maintenance therapy for bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lamotrigine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – Although evidence supporting the use of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> monotherapy for bipolar I major depression is not compelling, administering lithium is consistent with multiple treatment guidelines [<a href="#rid11">11,50-52</a>]. Using lithium is advantageous in that the drug has demonstrated efficacy for maintenance treatment and may reduce the risk of suicide [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'</a>.)</p><p></p><p class="bulletIndent1">The starting dose and dose-titration schedule for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, as well as the use of lithium serum concentrations to adjust the dose, are discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Prescribing lithium'</a>.)</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for treating bipolar major depression includes a review of nine small controlled trials (total n = 163) that were conducted in 1960s and 1970s; eight of the nine studies found that lithium was superior to placebo [<a href="#rid53">53</a>]. However, methodologic problems beyond the small sample sizes include the use of a nonrandom crossover design in many of the studies. As an example, the largest study was a crossover trial in which hospitalized patients with bipolar I or II disorder (n = 40) were initially treated with placebo for at least six days, followed by lithium for a minimum of two weeks, which was then followed by a second round of placebo; patients and clinical raters were both blind to the prescribed study drug [<a href="#rid54">54</a>]. Depressive symptoms were greater during treatment with placebo than lithium.</p><p></p><p class="bulletIndent1">However, other studies indicate that <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> may not be beneficial for bipolar major depression. As an example, a relatively large and recent eight-week randomized trial compared lithium with placebo in patients with bipolar I or II disorder (n = 265) [<a href="#rid18">18</a>]. Improvement of depressive symptoms, as well as response and remission, were each comparable for lithium and placebo. It appears that problems with adverse effects (eg, dry mouth, nausea, and tremor) limited the benefit of lithium; although the target serum concentration was 0.6 to 1.2 mEq/L (0.6 to 1.2 mmol/L), the average lithium serum concentration was only 0.6 mEq/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olanzapine</strong> – The efficacy of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> monotherapy for acute bipolar I major depression is well established, based upon randomized trials that compared the drug with placebo [<a href="#rid9">9,28</a>]. As an example, a network meta-analysis of 29 randomized trials evaluated the efficacy of 13 medication regimens in patients who were treated for 4 to 16 weeks (n &gt;8000) [<a href="#rid28">28</a>]. The analysis ranked the efficacy of medications by using results from direct comparisons between the drugs, as well as indirectly comparing drugs through their relative effect with a common comparator (typically placebo). The second most efficacious drug regimen was olanzapine. In addition, using olanzapine is advantageous in that the drug has demonstrated efficacy for maintenance treatment. However, olanzapine monotherapy is less effective than olanzapine plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> is reserved as a third-line treatment for bipolar major depression because of problematic metabolic side effects. We typically do not use olanzapine monotherapy in patients who have not responded to olanzapine plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>. (See <a class="local">'Second-line medications'</a> above.)</p><p></p><p class="bulletIndent1">The starting dose of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> is typically 5 mg once daily at bedtime [<a href="#rid29">29,30</a>]. The dose can then be titrated up by increments of 5 mg/day every one to seven days, depending upon efficacy and tolerability; the maximum dose is to 20 mg/day. For patients sensitive to adverse effects, the dose can be started at 2.5 mg/day, titrated up to 2.5 or 5 mg/day within one to seven days, and further titrated by 5 mg/day every one to seven days.</p><p></p><p class="bulletIndent1">The efficacy and adverse effects of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> for acute bipolar major depression and for maintenance treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Olanzapine'</a> and  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Olanzapine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbamazepine</strong> – <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> monotherapy may help patients with acute bipolar I major depression, and has also been used as maintenance treatment [<a href="#rid9">9,11</a>]. However, its clinical use is limited by the potential for severe adverse effects (eg, rash, aplastic anemia, and liver toxicity) and significant drug-drug interactions due to induction of cytochrome P450 enzymes.</p><p></p><p class="bulletIndent1">The administration of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, the use of serum concentrations to guide dosing, and side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 6</a>) are discussed separately in the context treating bipolar mania and treating epilepsy. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Carbamazepine'</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a>.)</p><p></p><p class="bulletIndent1">Specific interactions of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> for acute bipolar I major depression includes a 12-week randomized trial, which compared carbamazepine (mean dose 452 mg/day) with placebo in patients with bipolar I or II major depression (n = 74) [<a href="#rid55">55</a>]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received carbamazepine than placebo (64 versus 35 percent). In addition, discontinuation of treatment was comparable for carbamazepine and placebo (4 and 0 percent).</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> as maintenance treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Carbamazepine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cariprazine</strong> – For acute treatment of bipolar I major depression, <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a> monotherapy is started at 1.5 mg/day. If patients do not respond after one to two weeks and are tolerating the drug, increase the dose to 3 mg/day; the maximum dose is 3 mg/day [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a> for bipolar I major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Cariprazine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><strong>olanzapine</strong><strong> plus </strong><strong>lithium</strong><strong> or </strong><strong>valproate</strong> – The use of these medication regimens is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antimanic drug combinations (eg, </strong><strong>lithium</strong><strong> plus </strong><strong>carbamazepine</strong><strong>)</strong> – The use of these medication regimens is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><strong>lithium</strong><strong> or </strong><strong>valproate</strong><strong> plus an antidepressant such as an SSRI (eg, </strong><strong>fluoxetine</strong><strong>) or </strong><strong>bupropion</strong> – The use of these medication regimens is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with a second-generation antipsychotic (usually </strong><strong>quetiapine</strong><strong>, </strong><strong>lurasidone</strong><strong>, or </strong><strong>olanzapine</strong><strong>) plus an antidepressant</strong> – The use of these medication regimens is discussed elsewhere in this topic. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="headingAnchor" id="H3883263491"><span class="h3">Treatment-refractory patients</span><span class="headingEndMark"> — </span>For patients with bipolar major depression who are severely ill (eg, persistent suicidal ideation with a plan) and have not responded to multiple (eg, three to five) pharmacotherapy trials, we suggest ECT [<a href="#rid9">9-12,14,15,57</a>]. However, there are no established criteria for the number or duration of unsuccessful drug trials prior to initiating ECT. The use of ECT for bipolar major depression is consistent with multiple practice guidelines [<a href="#rid10">10,11,14-16</a>].</p><p>ECT frequently provides a rapid clinical response and may thus be indicated as initial treatment in urgent clinical situations that are life-threatening or characterized by gross impairment of functioning, including patients with [<a href="#rid9">9-11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe suicidal behavior, such as patients who survive a suicide attempt and wish they had succeeded – (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe psychosis, such as patients with persistent auditory hallucinations characterized by commands to kill oneself – (See  <a class="medical medical_review" href="/d/html/17193.html" rel="external">"Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant catatonia, which is characterized by signs of catatonia  (<a class="graphic graphic_table graphicRef53391" href="/d/graphic/53391.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef66229" href="/d/graphic/66229.html" rel="external">table 9</a>) along with fever, autonomic instability, delirium, and rigidity – (See  <a class="medical medical_review" href="/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Malignant catatonia'</a> and  <a class="medical medical_review" href="/d/html/15869.html" rel="external">"Catatonia: Treatment and prognosis", section on 'Malignant catatonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration and malnutrition in patients with fluid and food refusal secondary to depressive illness.</p><p></p><p>ECT may be less risky than antidepressant and antipsychotic medication for certain patients, including those who are debilitated and older (eg, ≥65 years). Pregnant and lactating patients worried about teratogenesis and other medication side effects can also be effectively and safely treated with ECT. Patients may prefer ECT and request it as a first-line treatment if, for example, the patient has a history of a depressive episode that was successfully treated with ECT after failing multiple medication trials.</p><p>Separate topics provide an overview of ECT (including pre-ECT evaluation, use of concurrent medications, treatment course, and adverse effects), and discuss the indications for and efficacy of ECT in bipolar major depression, the medical consultation for ECT, and the technique for performing ECT. (See  <a class="medical medical_review" href="/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults"</a> and  <a class="medical medical_review" href="/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults"</a>.)</p><p class="headingAnchor" id="H932784679"><span class="h1">ANXIETY, INSOMNIA, OR AGITATION</span><span class="headingEndMark"> — </span>Managing bipolar I or II major depressive episodes that include prominent symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or mild to moderate psychomotor agitation depends upon the primary (foundational) pharmacotherapy regimen that is prescribed:</p><p class="bulletIndent1"><span class="glyph">●</span>If patients are not receiving a sedating medication, such as <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, we generally add a benzodiazepine, such as <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 0.5 to 1 mg one to three times/day, on a temporary basis (eg, 6 to 12 weeks). If the anxiety, insomnia, or mild to moderate psychomotor agitation do not resolve within a few weeks (eg, two to three), we suggest discontinuing the benzodiazepine in favor of add-on pharmacotherapy with a different drug. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients are receiving a sedating medication, we typically titrate up the dose of the drug within the therapeutic range, until the symptoms resolve. If the anxiety, insomnia, or mild to moderate psychomotor agitation do not resolve within a few weeks, we suggest add-on pharmacotherapy with a different drug. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p>Anxiety symptoms that are part of a depressive syndrome are distinguished from anxiety disorders. Treatment of anxiety disorders is discussed separately.</p><p>Treatment of patients with bipolar disorder and acute, severe agitation is discussed separately in the context of mania. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Agitation'</a>.)</p><p class="headingAnchor" id="H2572147893"><span class="h1">PARTIAL RESPONSE</span><span class="headingEndMark"> — </span>Patients with bipolar I or II major depression who are treated with an antimanic drug may achieve a partial, clinically meaningful response, but continue to suffer significant symptoms. For these patients we suggest add-on pharmacotherapy. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p class="headingAnchor" id="H23270396"><span class="h1">BREAKTHROUGH BIPOLAR I MAJOR DEPRESSION DESPITE ONGOING ANTIMANIC DRUG THERAPY</span><span class="headingEndMark"> — </span>New episodes of major depression can occur in patients with bipolar I disorder who previously responded to and continued antimanic drug therapy (see <a class="local">'Antimanic drug'</a> above) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3760617880"><span class="h2">General approach</span><span class="headingEndMark"> — </span>For bipolar I major depressive episodes that occur despite ongoing antimanic drug therapy (see <a class="local">'Antimanic drug'</a> above), management begins with a clinical evaluation that identifies and addresses common reasons for breakthrough episodes [<a href="#rid9">9-11,15,59-62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor adherence to treatment – Identify and address barriers to adequate adherence. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate dose of the antimanic drug – Optimize dose of the antimanic drug. (See <a class="local">'Optimize dose of the antimanic drug'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-drug interactions may render antimanic drugs less effective or increase adverse effects – Specific interactions of antimanic drugs with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substance abuse may destabilize the patient’s mood – Identify and address substance abuse; multiple topics in UpToDate discuss management of substance use disorders. (See  <a class="medical medical_review" href="/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant medications may destabilize the patient’s mood – Discontinue medications that may induce mood instability (eg, antidepressants, caffeine, steroids, stimulants, and sympathomimetics), particularly if the medications have not been clearly effective or are correlated in time with depression onset or worsening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increases in psychosocial stress or significant disruption of regular social rhythms and daily routine – Adjunctive psychotherapy can be useful for targeting problems that provoked the current depressive episode, including difficulties with relationships or stress at work, dysfunctional thoughts and/or behavior, and disruption of social rhythms. (See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment", section on 'Adjunctive psychotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disease in patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>. (See  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid", section on 'Thyroid disease in lithium-treated patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insufficient antidepressive efficacy of the current antimanic drug – In many cases, monotherapy with the current antimanic drug at therapeutic doses does not provide sufficient antidepressive efficacy, and add-on treatment is needed. (See <a class="local">'Add-on pharmacotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suboptimal efficacy of the antimanic drug with regard to preventing recurrence of major depression – Patients who respond to treatment of an acute mood episode with an antimanic drug typically continue that drug as maintenance therapy. However, the drug may fail as maintenance therapy or may initially prevent recurrences of mood episodes and subsequently fail. Choosing maintenance therapy, after successfully treating the breakthrough episode of bipolar I major depression, is discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p></p><p class="headingAnchor" id="H23270402"><span class="h2">Optimize dose of the antimanic drug</span><span class="headingEndMark"> — </span>For patients taking <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, serum concentrations should be measured to evaluate adherence and adequacy of dosing [<a href="#rid9">9,10,13,17</a>]. If the serum concentration is subtherapeutic and the patient has had reasonably good adherence (eg, taking 80 percent of prescribed doses), the dose of carbamazepine, lithium, or valproate should be increased to achieve serum levels that are within the therapeutic range. The dose and therapeutic range of serum concentrations are discussed separately in the context of treating acute mania. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Medication doses and side effects'</a>.)</p><p>For patients with bipolar major depression who are taking low doses of second-generation antipsychotic drugs (eg, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>), we suggest increasing the daily medication dose to the minimum dose found to be effective for new bipolar depressive episodes in randomized trials, and if the depressive episode persists, to progressively titrate the dose up to the maximum tolerated within the therapeutic dose range. The administration of second-generation antipsychotics is discussed elsewhere in this topic. (See <a class="local">'First-line medications'</a> above and <a class="local">'Third-line medications'</a> above.)</p><p>For patients with bipolar I major depression who are treated with second-generation antipsychotics or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, therapeutic serum concentrations have not been established [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H23270408"><span class="h2">Add-on pharmacotherapy</span><span class="headingEndMark"> — </span>Many patients suffer breakthrough episodes of bipolar I major depression because of insufficient antidepressive efficacy of the current antimanic drug. For these patients, we suggest adjunctive pharmacotherapy rather than other approaches, such as switching medications [<a href="#rid9">9</a>].</p><p>For bipolar patients with either breakthrough major depression or major depression unresponsive to monotherapy, choosing a specific drug for add-on pharmacotherapy depends upon the current (ongoing) antimanic drug therapy, ie, whether patients are currently treated with:</p><p class="bulletIndent1"><span class="glyph">●</span>A second-generation antipsychotic, or</p><p class="bulletIndent1"><span class="glyph">●</span>Another antimanic drug (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a></p><p></p><p>Relatively few randomized trials have studied breakthrough bipolar major depression or major depression unresponsive to monotherapy; thus, selecting a drug for augmentation is typically based upon studies conducted in patients who present with acute bipolar I major depression in the absence of current antimanic drug therapy. (See <a class="local">'Bipolar I major depression, no antimanic drug therapy'</a> above.)</p><p>Observational studies consistently show that many patients with bipolar disorder receive psychotropic polypharmacy [<a href="#rid63">63</a>]; one retrospective study of patients hospitalized with bipolar depression (n &gt;2200) over a 15-year period found that nearly 85 percent received at least two concurrent psychotropic drugs [<a href="#rid64">64</a>]. However, adherence to treatment may be worse with medication combinations than monotherapy [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H2873792637"><span class="h3">Currently treated with a second-generation antipsychotic</span><span class="headingEndMark"> — </span>For patients who are currently treated with a second-generation antipsychotic and require a second drug to manage acute bipolar major depression, we suggest add-on treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid9">9</a>]. This approach is consistent with multiple practice guidelines [<a href="#rid11">11,14,15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong> – For patients with bipolar major depression who are treated with a second-generation antipsychotic and require a second drug, augmentation with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> can be beneficial. In addition, lamotrigine has established efficacy as maintenance therapy for bipolar disorder. Thus, if an acutely ill patient responds to lamotrigine plus another drug (eg, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>), but the other drug proves to be intolerable during maintenance therapy, the other drug can readily be discontinued, leaving the patient with lamotrigine monotherapy for maintenance therapy [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">The starting dose, dose-titration schedule, and adverse effects of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> are discussed elsewhere in the topic. (See <a class="local">'Third-line medications'</a> above.)</p><p></p><p class="bulletIndent1">Evidence supporting augmentation of second-generation antipsychotics with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> includes a study that enrolled 202 patients with bipolar I or II depression who had not responded to pharmacotherapy (eg, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, and antidepressants) and treated them with open-label quetiapine (target dose 300 mg/day) for one to two weeks [<a href="#rid67">67</a>]. Patients were then randomly assigned to add-on lamotrigine (target dose 200 mg/day) or placebo for 12 weeks, during which both groups continued to receive quetiapine. In addition, medications prescribed at the time of enrollment were continued if clinically indicated. Remission occurred in more patients treated with adjunctive lamotrigine than placebo (31 versus 16 percent), and the benefit of lamotrigine was maintained at the 52-week follow-up assessment.</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> as maintenance therapy for bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lamotrigine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – The starting dose and dose-titration schedule for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, as well as the use of lithium serum concentrations to adjust the dose, are discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Prescribing lithium'</a>.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is used as add-on treatment for bipolar major depression, clinicians should try to achieve a serum concentration between 0.8 and 1.2 mEq/L (0.8 and 1.2 mmol/L). Serum levels should generally not exceed 1.2 mEq/L due to potential toxicity. Patients who cannot tolerate a level of 0.8 mEq/L may respond to a level of 0.6 mEq/L (0.6 mmol/L); however, serum concentrations less than 0.6 mEq/L often appear to be ineffective. As an example, a six-month, open-label randomized trial enrolled 283 acutely ill patients with bipolar I or II disorder who were suffering primarily symptoms of depression despite ongoing pharmacotherapy and randomly assigned them to add-on treatment with lithium or to no add-on treatment [<a href="#rid68">68</a>]. Throughout treatment with adjunctive lithium, serum concentrations averaged 0.4 to 0.5 mEq/L (0.4 and 0.5 mmol/L), and improvement of depressive symptoms in the group that received lithium and the control group was comparable. Additional information about serum lithium concentrations is discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong> – The administration of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> is discussed separately. (See <a class="local">'Second-line medications'</a> above.)</p><p></p><p class="bulletIndent1">Clinicians using adjunctive <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> should note that the drug can inhibit enzymatic metabolism of other drugs. Specific interactions of valproate with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p></p><p>Augmentation with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> may be declined due to either a prior history of poor response or to potential side effects that are unacceptable; a reasonable alternative to these three drugs is add-on treatment with an antidepressant, such as a serotonin reuptake inhibitor (eg, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>) or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid9">9</a>]. We suggest that clinicians avoid using antidepressants in patients with bipolar major depression who have previously experienced poor outcomes with antidepressant treatment, including patients with a history of treatment-emergent switching to mania/hypomania, rapid cycling, or suicidal ideation and behavior. In addition, we generally avoid antidepressants in patients with concurrent manic symptoms, substance use disorders, early age of onset of bipolar disorder, and a recent history of mania or hypomania. Although the use of antidepressants to treat bipolar I major depression is controversial, there is a limited role for these drugs as adjuncts to antimanic drugs in some patients. The role of antidepressants in treating bipolar I major depression, including their efficacy and potential adverse effects, including the potential risk of switching to mania, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p>If a patient treated with an adjunctive antidepressant switches to mania or hypomania, clinicians should immediately discontinue the antidepressant [<a href="#rid31">31</a>]. However, abruptly stopping the antidepressant may cause discontinuation symptoms. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults"</a>.)</p><p>For patients with bipolar I major depression who are treated with a second-generation antipsychotic, we suggest avoiding augmentation with another second-generation antipsychotic. Although no high quality studies have evaluated this approach, a prospective observational study followed patients with bipolar I or II disorder who were treated with either second-generation antipsychotic monotherapy (n = 1796) or multiple concurrent second-generation antipsychotics (n = 162); the average length of follow-up was 21 months [<a href="#rid69">69</a>]. The use of multiple concurrent second-generation antipsychotics did not appear to confer any benefit and was associated with increased side effect burden, including dry mouth, tremor, sedation, sexual dysfunction, and constipation.</p><p class="headingAnchor" id="H821708984"><span class="h3">Currently treated with other antimanic drugs or lamotrigine</span><span class="headingEndMark"> — </span>For bipolar patients who are currently treated with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and who require a second drug to manage acute major depression, we suggest add-on treatment with a second-generation antipsychotic [<a href="#rid9">9</a>]. Our order of preference is:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">Lurasidone</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a></p><p></p><p>Augmentation with a second-generation antipsychotic is consistent with practice guidelines [<a href="#rid11">11</a>]. The administration, efficacy, and adverse effects of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> in patients with bipolar major depression is discussed elsewhere. (See <a class="local">'First-line medications'</a> above and <a class="local">'Third-line medications'</a> above and  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p>Patients with bipolar I major depression may decline adjunctive second-generation antipsychotics, due to either a prior history of poor response or to potential side effects that are unacceptable. A reasonable alternative to second-generation antipsychotics is add-on treatment with an antidepressant, such as a serotonin reuptake inhibitor (eg, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>) or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid9">9</a>]. Although the use of antidepressants to treat bipolar I major depression is controversial, there is a limited role for these drugs as adjuncts to antimanic drugs. The role of antidepressants in bipolar I major depression, as well as their efficacy and potential adverse effects, including the risk of switching to mania, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p>If a patient treated with an adjunctive antidepressant switches to mania or hypomania, clinicians should immediately discontinue the antidepressant [<a href="#rid31">31</a>]. However, abruptly stopping the antidepressant may cause discontinuation symptoms. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults"</a>.)</p><p>For bipolar patients who are currently treated with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and who require a second drug to manage acute major depression, it is also reasonable to combine two of these drugs, such as [<a href="#rid9">9,11,14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a></p><p></p><p>Caution is required when combining <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> due to the increased risk of lamotrigine-induced severe skin rashes, including Stevens-Johnson syndrome. Valproate can inhibit enzymatic metabolism of other drugs, including lamotrigine. If the two drugs are combined, doses of lamotrigine must be lower (eg, by 50 percent) and the dose-titration schedule for the adjunctive drug must be more conservative. Specific interactions of valproate with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. Information about prescribing lamotrigine, valproate, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is discussed elsewhere in this topic. (See <a class="local">'Second-line medications'</a> above and <a class="local">'Third-line medications'</a> above.)</p><p>Multiple randomized trials indicate that add-on therapy with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> can be efficacious for bipolar major depression [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week trial enrolled patients with bipolar I or II major depression who had not responded to <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (n = 124) and randomly assigned them to add-on treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> (target dose of 200 mg/day by week 7) or placebo [<a href="#rid71">71</a>]. Response (reduction of baseline symptoms ≥50 percent) was greater with add-on lamotrigine than placebo (52 versus 32 percent). The incidence of each side effect that occurred (eg, headache, fatigue, nausea, flu-like symptoms, or any rash) was comparable in the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 16-week, open-label trial enrolled patients with bipolar I or II major depression (n = 66) who had not responded to combined treatment with antimanic drugs plus antidepressants and randomly assigned them to add-on treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> (target dose 150 to 250 mg/day), <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (0.5 to 6 mg/day), or inositol (target dose 10 to 25 mg/day) [<a href="#rid72">72</a>]. Patients were allowed to refuse randomization to any one of the three options. Improvement of depressive symptoms and functioning was greater with lamotrigine than risperidone or inositol.</p><p></p><p>Limited evidence supports the combination of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> (divalproex). A six-week randomized trial enrolled 27 patients who suffered a breakthrough episode of bipolar I or II major depression despite maintenance treatment with lithium or divalproex monotherapy and randomly assigned them to either lithium plus divalproex or to add-on <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> (lithium plus paroxetine or divalproex plus paroxetine) [<a href="#rid73">73</a>]. Improvement of depressive symptoms and functioning with lithium/divalproex and with paroxetine augmentation was comparable. However, the small sample and lack of a placebo arm limits interpretation of the results.</p><p class="headingAnchor" id="H3690080973"><span class="h1">BIPOLAR II MAJOR DEPRESSION</span></p><p class="headingAnchor" id="H3782359182"><span class="h2">Choosing treatment</span><span class="headingEndMark"> — </span>We treat bipolar II major depression in the same manner as bipolar I major depression. Thus:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for patients with bipolar II major depression who not currently receiving antimanic drug therapy (see <a class="local">'Antimanic drug'</a> above) is the same as it is for bipolar I patients. (See <a class="local">'Bipolar I major depression, no antimanic drug therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for patients with breakthrough episodes bipolar II major depression despite ongoing antimanic drug therapy is the same as it is for bipolar I patients. (See <a class="local">'Breakthrough bipolar I major depression despite ongoing antimanic drug therapy'</a> above.)</p><p></p><p>Treatment of bipolar II major depression follows the practices established for bipolar I major depression because the large majority of patients in treatment studies had bipolar I disorder rather than bipolar II disorder [<a href="#rid9">9</a>]. As an example, in a pooled analysis of 24 randomized trials that compared active drugs (eg, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) with placebo for treating bipolar major depression (n &gt;7000 patients), more than 85 percent had bipolar I disorder [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3748591645"><span class="h2">Drug studies specific for bipolar II major depression</span><span class="headingEndMark"> — </span>Relatively few randomized trials have focused upon bipolar II major depression, compared with bipolar I major depression [<a href="#rid42">42</a>]. In addition, many of the bipolar II trials had methodologic shortcomings, such as open-label administration of study drugs and lack of a placebo arm, which makes it difficult to interpret the results.</p><p>The following drugs have been studied in randomized trials that focused upon patients with bipolar II major depression [<a href="#rid74">74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quetiapine</strong><strong> compared with placebo</strong> – Multiple randomized trials in patients with bipolar II major depression have demonstrated that <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> (300 or 600 mg at bedtime) is efficacious. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Bipolar II major depression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong><strong> compared with placebo</strong> – An eight-week randomized trial compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> (target dose 200 mg/day) with placebo in patients with bipolar II depression (n = 214); improvement with lamotrigine and placebo was comparable, such that response (reduction of baseline symptoms ≥50 percent) occurred in roughly 50 percent of patients in each group [<a href="#rid45">45</a>]. However, the lack of benefit seen with lamotrigine may have been due to the six-week dose-titration schedule required to reach the target dose, in a trial that lasted only eight weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong><strong> compared with </strong><strong>lithium</strong> – An open-label, 16-week randomized trial compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> (target dose 100 to 200 mg/day) with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (target serum concentration 0.6 to 1.2 mEq/L [0.6 to 1.2 mmol/L]) in 90 patients with bipolar II depression [<a href="#rid75">75</a>]. Remission was comparable with lamotrigine and lithium (66 and 55 percent of patients). Although discontinuation of treatment was identical in each group (20 percent), the mean number of side effects was lower with lamotrigine than lithium (four versus nine). Interpretation of this study is limited by the large number of patients who discontinued treatment for any reason (56 percent overall) and lack of a placebo arm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong><strong> compared with </strong><strong>venlafaxine</strong> – An open-label, 12-week randomized trial compared <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (target serum concentration 0.5 to 1.5 mEq/L [0.5 to 1.5 mmol/L]) with <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (37.5 to 375 mg/day) in 83 patients with bipolar II major depression [<a href="#rid76">76</a>]. Improvement of depression was greater with venlafaxine than lithium, and switching to hypomania was comparable for the two groups (one patient in each group).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong><strong> compared with </strong><strong>lithium</strong><strong> plus </strong><strong>sertraline</strong> – A 16-week randomized trial compared <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus placebo with lithium plus <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> in patients with bipolar II major depression (n = 97) [<a href="#rid77">77</a>]. The mean serum lithium concentration in both groups was approximately 0.6 mEq/L (0.6 mmol/L); the minimum target dose of sertraline was 100 mg/day. Response (reduction of baseline symptoms ≥50 percent) was comparable in patients who received lithium alone and lithium plus sertraline (67 and 48 percent). Although the difference between treatments was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful. Switching to hypomania was comparable with lithium and lithium plus sertraline (19 and 13 percent of patients), as was discontinuation of treatment due to side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive antidepressant compared with placebo</strong> – A 26-week randomized trial found that response to antidepressants plus antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) was comparable in patients with bipolar II depression (n = 54) and patients with bipolar I depression (n = 118; 20 and 25 percent) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1">In addition, other studies suggest that adjunctive antidepressants may be less likely to induce switching to mania or hypomania in patients with bipolar II major depression than patients with bipolar I major depression. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Clinical risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H2790231860"><span class="h1">BIPOLAR I OR II MAJOR DEPRESSION WITH PSYCHOTIC FEATURES</span><span class="headingEndMark"> — </span>Episodes of major depression in bipolar I disorder or bipolar II disorder can include psychotic features, such as delusions or hallucinations [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features", section on 'Psychosis'</a>.)</p><p>For treatment of bipolar I or II major depression with psychotic features, standard treatment consists of a regimen that includes an antipsychotic drug [<a href="#rid11">11,79</a>]. The specific choice of an antipsychotic is discussed elsewhere in this topic. (See <a class="local">'Bipolar I major depression, no antimanic drug therapy'</a> above and <a class="local">'Add-on pharmacotherapy'</a> above.)</p><p>Treatment-resistant bipolar major depression with psychotic features that does not respond to multiple trials of pharmacotherapy is treated with electroconvulsive therapy [<a href="#rid11">11</a>]. However, electroconvulsive therapy frequently provides a rapid clinical response and may thus be indicated as initial treatment in certain urgent clinical situations that are life-threatening or characterized by gross impairment of functioning. (See <a class="local">'Treatment-refractory patients'</a> above.)</p><p class="headingAnchor" id="H2072461591"><span class="h1">RAPID CYCLING BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Treatment of major depression in patients with rapid cycling bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression"</a>.)</p><p class="headingAnchor" id="H3757925804"><span class="h1">BIPOLAR I OR II MAJOR DEPRESSION WITH SEASONAL PATTERN</span><span class="headingEndMark"> — </span>We treat bipolar I and bipolar II major depression with seasonal pattern in the same manner as bipolar I major depression without seasonal pattern. Thus:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for patients with bipolar major depression with seasonal pattern who are not currently receiving antimanic drug therapy (see <a class="local">'Antimanic drug'</a> above) is the same as it is for bipolar I patients. (See <a class="local">'Bipolar I major depression, no antimanic drug therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for patients with breakthrough episodes of bipolar major depression with seasonal pattern despite ongoing antimanic drug therapy is the same as it is for bipolar I patients. (See <a class="local">'Breakthrough bipolar I major depression despite ongoing antimanic drug therapy'</a> above.)</p><p></p><p>However, for patients with bipolar major depression with seasonal pattern who do not respond to standard treatments, it is reasonable to attempt a trial of adjunctive bright light therapy. (See  <a class="medical medical_review" href="/d/html/101250.html" rel="external">"Seasonal affective disorder: Treatment", section on 'Bipolar disorder with seasonal pattern'</a>.)</p><p class="headingAnchor" id="H817848992"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1328858567"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>Treatment of bipolar major depression during pregnancy and the teratogenic and postnatal risks of pharmacotherapy for bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/82788.html" rel="external">"Bipolar disorder in pregnant women: Treatment of major depression"</a> and  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p class="headingAnchor" id="H3317830848"><span class="h2">Postpartum patients</span><span class="headingEndMark"> — </span>Treatment of postpartum patients with bipolar major depression, including patients who are breastfeeding, is discussed separately, as is the safety of infant exposure to psychotropic drugs through breastfeeding. (See  <a class="medical medical_review" href="/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment", section on 'Breastfeeding patients'</a> and  <a class="medical medical_review" href="/d/html/93451.html" rel="external">"Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders"</a> and  <a class="medical medical_review" href="/d/html/1720.html" rel="external">"Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding"</a>.)</p><p class="headingAnchor" id="H1478502804"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>Treatment of pediatric bipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H3735480303"><span class="h2">Geriatric patients</span><span class="headingEndMark"> — </span>Treatment of geriatric bipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p class="headingAnchor" id="H3608906879"><span class="h1">INVESTIGATIONAL AND NONSTANDARD APPROACHES</span><span class="headingEndMark"> — </span>Investigational and nonstandard approaches for treating bipolar major depression are discussed separately. (See  <a class="medical medical_review" href="/d/html/115481.html" rel="external">"Bipolar major depression in adults: Investigational and nonstandard approaches to treatment"</a>.)</p><p class="headingAnchor" id="H1669755482"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H3968992164"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (See  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H23270445"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The general principles and issues that are involved in treating bipolar major depression include the initial assessment, goals of treatment, setting, pharmacotherapy, duration of an adequate drug trial, monitoring, adjunctive psychotherapy, and comorbidity. (See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bipolar I major depression in patients who are not receiving antimanic drugs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Usual approach – Patients with bipolar I disorder often present with major depression in the absence of antimanic drug therapy. For these patients, we suggest initial treatment with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients unresponsive to the first drug are switched to the other drug. (See <a class="local">'First-line medications'</a> above and  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Life-threatening illness – Electroconvulsive therapy frequently provides a rapid clinical response and may thus be indicated as initial treatment in life-threatening clinical situations. (See <a class="local">'Treatment-refractory patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment-resistant illness</strong> – Patients with bipolar I major depression may not respond to or tolerate <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy and <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> monotherapy. Second-line treatment options for these patients include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> monotherapy</p><p class="bulletIndent3"><span class="glyph">-</span>Combination therapy with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a></p><p class="bulletIndent3"><span class="glyph">-</span>Combination therapy with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a></p><p></p><p class="bulletIndent2">(See <a class="local">'Second-line medications'</a> above and <a class="local">'Add-on pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Highly resistant/refractory illness</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Usual approach – Patients with bipolar I major depression may not respond to first and second-line medications. For these patients, treatment options include monotherapy with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, or <a class="drug drug_general" data-topicid="104184" href="/d/drug information/104184.html" rel="external">cariprazine</a>; combination therapy with olanzapine plus lithium or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>; other antimanic drug combinations (eg, lithium plus carbamazepine); combination therapy with lithium or valproate plus an antidepressant; and combination therapy with a second-generation antipsychotic plus an antidepressant. (See <a class="local">'Third-line medications'</a> above and <a class="local">'Add-on pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe illness – Patients with bipolar major depression who are severely ill and do not respond to first-, second-, or third-line medications are treated with electroconvulsive therapy. (See <a class="local">'Treatment-refractory patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breakthrough episodes of bipolar I major depression despite ongoing antimanic drug therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General approach</strong> – New episodes of major depression can occur in patients with bipolar I disorder who previously responded to and continued antimanic drug therapy. Initial management includes a clinical evaluation that identifies and addresses common reasons for breakthrough episodes, such as poor adherence, inadequate dose of the antimanic drug, substance abuse, psychosocial stress, and insufficient antidepressive efficacy of the current antimanic drug. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Add-on pharmacotherapy</strong> – For breakthrough episodes of bipolar I major depression that are due to insufficient antidepressive efficacy of the current antimanic drug, we suggest add-on pharmacotherapy rather than switching (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The specific choice depends upon the current antimanic drug therapy:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who are currently treated with a second-generation antipsychotic are generally prescribed add-on <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>. (See <a class="local">'Currently treated with a second-generation antipsychotic'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who are currently treated with an antimanic drug other than a second-generation antipsychotic generally receive an adjunctive second-generation antipsychotic. Our order of preference is <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>. (See <a class="local">'Currently treated with other antimanic drugs or lamotrigine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other patients with bipolar major depression</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bipolar II major depression</strong> – We treat bipolar II major depression in the same manner as bipolar I major depression. (See <a class="local">'Bipolar II major depression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seasonal pattern</strong> – We treat bipolar I or II major depression with seasonal pattern in the same manner as bipolar I major depression without seasonal pattern. (See <a class="local">'Bipolar I or II major depression with seasonal pattern'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psychotic features</strong> – Standard treatment of bipolar I or II major depression with psychotic features includes an antipsychotic drug. Patients who do not respond to pharmacotherapy or who have life-threatening symptoms may require electroconvulsive therapy. (See <a class="local">'Bipolar I or II major depression with psychotic features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rapid cycling</strong> – (See  <a class="medical medical_review" href="/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy</strong> – (See  <a class="medical medical_review" href="/d/html/82788.html" rel="external">"Bipolar disorder in pregnant women: Treatment of major depression"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postpartum</strong> – (See  <a class="medical medical_review" href="/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment", section on 'Bipolar major depression'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pediatric</strong> – (See  <a class="medical medical_review" href="/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Geriatric</strong> – (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p></p><p class="headingAnchor" id="H2259783487"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Jeffrey Stovall, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.</a></li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a class="nounderline abstract_t">Simon GE, Bauer MS, Ludman EJ, et al. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68:1237.</a></li><li><a class="nounderline abstract_t">Rihmer Z. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2005; 2:48.</a></li><li><a class="nounderline abstract_t">McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009; 70 Suppl 3:5.</a></li><li><a class="nounderline abstract_t">Goes FS, Sadler B, Toolan J, et al. Psychotic features in bipolar and unipolar depression. Bipolar Disord 2007; 9:901.</a></li><li><a class="nounderline abstract_t">Swartz HA, Swanson J. Psychotherapy for Bipolar Disorder in Adults: A Review of the Evidence. Focus (Am Psychiatr Publ) 2014; 12:251.</a></li><li><a class="nounderline abstract_t">Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc 2017; 92:1532.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. National Clinical Guideline Number 185. September, 2014. https://www.nice.org.uk/guidance/cg185/evidence (Accessed on September 14, 2017).</li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.</a></li><li><a class="nounderline abstract_t">Ostacher MJ, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians. J Clin Psychiatry 2016; 77:920.</a></li><li><a class="nounderline abstract_t">Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014; 349:g5673.</a></li><li><a class="nounderline abstract_t">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.</a></li><li><a class="nounderline abstract_t">McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.</a></li><li><a class="nounderline abstract_t">Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.</a></li><li><a class="nounderline abstract_t">Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther 2014; 8:827.</a></li><li><a class="nounderline abstract_t">Kishi T, Ikuta T, Sakuma K, et al. Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. J Psychiatr Res 2019; 115:121.</a></li><li><a class="nounderline abstract_t">Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012; 27:76.</a></li><li><a class="nounderline abstract_t">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:160.</a></li><li><a class="nounderline abstract_t">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:169.</a></li><li><a class="nounderline abstract_t">Wang H, Xiao L, Wang HL, Wang GH. Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis. J Affect Disord 2020; 264:227.</a></li><li><a class="nounderline abstract_t">Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 2014; 130:452.</a></li><li><a class="nounderline abstract_t">Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.</a></li><li><a class="nounderline abstract_t">Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012; 201:376.</a></li><li><a class="nounderline abstract_t">Bowers MB Jr, McKay BG, Mazure CM. Discontinuation of antidepressants in newly admitted psychotic patients. J Neuropsychiatry Clin Neurosci 2003; 15:227.</a></li><li><a class="nounderline abstract_t">Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72:813.</a></li><li class="breakAll">Labbate, LA, Fava, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.</li><li class="breakAll">Bowden CL. Valproate. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.923.</li><li><a class="nounderline abstract_t">Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85:259.</a></li><li><a class="nounderline abstract_t">Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010; 32:19.</a></li><li><a class="nounderline abstract_t">Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.</a></li><li><a class="nounderline abstract_t">Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000; 48:573.</a></li><li><a class="nounderline abstract_t">Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 6:74.</a></li><li><a class="nounderline abstract_t">Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59:1078.</a></li><li><a class="nounderline abstract_t">Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64:200.</a></li><li><a class="nounderline abstract_t">Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47:43.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010; 122:1.</a></li><li><a class="nounderline abstract_t">Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010; 124:228.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10:323.</a></li><li><a class="nounderline abstract_t">Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194:4.</a></li><li><a class="nounderline abstract_t">Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27:173.</a></li><li><a class="nounderline abstract_t">Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry 2013; 74:675.</a></li><li class="breakAll">Lamotrigine. Highlights of Prescribing Information. 3/2021 : https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020241s064,020764s057,022251s028lbl.pdf (Accessed on April 21, 2021).</li><li><a class="nounderline abstract_t">Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord 2017; 217:266.</a></li><li><a class="nounderline abstract_t">Parker G, Malhi GS, Hamilton A, et al. Stepwise treatment of acute bipolar depression. Bipolar Disord 2019; 21:465.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li><a class="nounderline abstract_t">Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13:397.</a></li><li><a class="nounderline abstract_t">Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129:44.</a></li><li><a class="nounderline abstract_t">Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007; 41:360.</a></li><li><a class="nounderline abstract_t">Durgam S, Earley W, Lipschitz A, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry 2016; 173:271.</a></li><li><a class="nounderline abstract_t">Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord 2013; 15:61.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Psychiatry Rep 2005; 7:456.</a></li><li><a class="nounderline abstract_t">Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012; 14 Suppl 2:37.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.</a></li><li><a class="nounderline abstract_t">Hlastala SA. Stress, social rhythms, and behavioral activation: psychosocial factors and the bipolar illness course. Curr Psychiatry Rep 2003; 5:477.</a></li><li><a class="nounderline abstract_t">Sachs GS, Ketter TA. Update on best practices for managing bipolar depression. J Clin Psychiatry 2014; 75:e413.</a></li><li><a class="nounderline abstract_t">Fornaro M, De Berardis D, Koshy AS, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat 2016; 12:719.</a></li><li><a class="nounderline abstract_t">Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 2012; 12:153.</a></li><li><a class="nounderline abstract_t">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.</a></li><li><a class="nounderline abstract_t">Kini V, Ho PM. Interventions to Improve Medication Adherence: A Review. JAMA 2018; 320:2461.</a></li><li><a class="nounderline abstract_t">Geddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 2016; 3:31.</a></li><li><a class="nounderline abstract_t">Nierenberg AA, Friedman ES, Bowden CL, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry 2013; 170:102.</a></li><li><a class="nounderline abstract_t">Brooks JO 3rd, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 2011; 72:240.</a></li><li><a class="nounderline abstract_t">Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006; 96:95.</a></li><li><a class="nounderline abstract_t">van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:223.</a></li><li><a class="nounderline abstract_t">Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163:210.</a></li><li><a class="nounderline abstract_t">Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157:124.</a></li><li><a class="nounderline abstract_t">Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.</a></li><li><a class="nounderline abstract_t">Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111:334.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Wang CH, Shwarz M, Shults J. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord 2009; 112:219.</a></li><li><a class="nounderline abstract_t">Altshuler LL, Sugar CA, McElroy SL, et al. Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. Am J Psychiatry 2017; 174:266.</a></li><li><a class="nounderline abstract_t">Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711.</a></li><li><a class="nounderline abstract_t">Bjørklund LB, Horsdal HT, Mors O, et al. Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression. Bipolar Disord 2017; 19:505.</a></li></ol></div><div id="topicVersionRevision">Topic 15267 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044195" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The long-term natural history of the weekly symptomatic status of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854249" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prediction and prevention of suicide in bipolar disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076541" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychotic features in bipolar and unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279641" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Psychotherapy for Bipolar Disorder in Adults: A Review of the Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888714" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388529" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388529" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580001" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25258392" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessment and management of bipolar disorder: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122366" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994719" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110817" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25028535" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Quetiapine for acute bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128502" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22107783" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Quetiapine for bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170180" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170221" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056755" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25283309" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609883" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918966" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12724466" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Discontinuation of antidepressants in newly admitted psychotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816041" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816041" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780695" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Divalproex in the treatment of bipolar depression: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901867" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11011863" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11018228" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bipolar disorder therapeutics: maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9674940" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anticonvulsants and antipsychotics in the treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16448626" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18756476" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549862" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926140" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044142" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18271912" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756579" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety and tolerability of lamotrigine for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945444" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lamotrigine in psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945444" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lamotrigine in psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437764" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31016815" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Stepwise treatment of acute bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120153" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of depression in bipolar disorder: new directions for research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4556087" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lithium response in unipolar versus bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16081106" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541814" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190379" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16318824" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term remission and recovery in bipolar disorder: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510035" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment options for acute depression in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609503" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Stress, social rhythms, and behavioral activation: psychosocial factors and the bipolar illness course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922493" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Update on best practices for managing bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099503" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998655" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adherence to medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561486" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interventions to Improve Medication Adherence: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687300" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288387" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20868629" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820213" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200421" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449473" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10618026" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816033" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358540" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486235" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28135846" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392295" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effectiveness of adjunctive antidepressant treatment for bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28593691" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
